Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDC2301
- Development stage
- Preclinical
- Lead developer
- Prestige Biopharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
IDC2301 is a bispecific monoclonal antibody biosimilar developed by Prestige Biopharma (PBK) for the treatment of Hemophilia A. It is designed to mimic the function of activated Factor VIII (FVIIIa) by simultaneously binding to activated Factor IX (FIXa) and Factor X (FX). This bridging action facilitates the activation of Factor X, which is essential for the blood coagulation cascade and is impaired in patients with Hemophilia A due to FVIII deficiency or the presence of FVIII inhibitors. As a biosimilar to emicizumab (Hemlibra), IDC2301 is intended to provide a prophylactic treatment option to prevent or reduce the frequency of bleeding episodes. The candidate is currently in the preclinical stage of development.
- Other names
- emicizumab biosimilarFactor IXa/X-bispecific antibody
02
Targets
F10 (Factor Xa)Coagulation Factor IXa
Beyond the preview
Go deeper on IDC2301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDC2301.